Tier 2 — strong

Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole

Ricardo de Souza Pereira
Journal of pineal research 2006 41(3):195-200

Bibliography

PubMed
PMID 16948779
DOI
10.1111/j.1600-079X.2006.00359.x
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignRandomized single-blind RCT
ModelHuman participants
Sample351 patients with gastroesophageal reflux symptoms
InterventionMelatonin, tryptophan, vitamins, methionine and betaine combination versus omeprazole 20 mg/day
Duration40 days
EndpointsReflux symptoms; Tolerability

What the study showed, in plain terms

Published in 2006, this source examined brain health and combination interventions. Design: Randomized single-blind RCT. Sample/model: 351 patients with gastroesophageal reflux symptoms. The exposure or intervention was Melatonin, tryptophan, vitamins, methionine and betaine combination versus omeprazole 20 mg/day. Follow-up or treatment period: 40 days.

The multi-ingredient group reported a higher rate of complete symptom regression than the omeprazole comparison.

Single-blind symptom study with several active components. It does not show that TMG alone treats reflux, and the product was not betaine HCl acid replacement.

Continue with TMG Data Center

Continue with TMG Supplement: Trimethylglycine Benefits, Uses and Evidence

Key findings

  • The multi-ingredient group reported a higher rate of complete symptom regression than the omeprazole comparison.
  • The recorded outcome domains were Reflux symptoms; Tolerability.
  • The result applies to the tested exposure: Melatonin, tryptophan, vitamins, methionine and betaine combination versus omeprazole 20 mg/day; 40 days.

What this study can and cannot tell us

  • Single-blind symptom study with several active components. It does not show that TMG alone treats reflux, and the product was not betaine HCl acid replacement.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Betaine: A Promising Natural Product for Neurological and Psychiatric Diseases
Ying Zhang et al. · Current neuropharmacology · 2026
Tier 2
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients
D Knopman et al. · Alzheimer disease and associated disorders · 2001
Tier 2
A study of the treatment of Rett syndrome with folate and betaine
Daniel G Glaze et al. · Journal of child neurology · 2009
Tier 2
A placebo-controlled trial of folic acid and betaine in identical twins with Angelman syndrome
Julia Han et al. · Orphanet journal of rare diseases · 2019
Tier 2
Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression
Francesco Di Pierro et al. · International journal of general medicine · 2015

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology